May 16, 2019
Pharming Group net profit up for Q1 2019
Revenues increased approximately 19.5% to €35.2 million, compared with €29.5 million during the same period last year.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
May 16, 2019
4D pharma’s Chron’s treating Thetanix meets objective
4D pharma’s study of Thetanix for treating Crohn’s disease has met primary objective, as it showed Thetanix was well tolerated with a good safety profile.
May 16, 2019
ChargePoint Technology boosts UK presence with new appointment
Contained and sterile transfer solutions expert, ChargePoint Technology, has appointed Stephen Eastick as UK Sales Manager.
May 13, 2019
Lilly gets fifth FDA approval for Cyramza
Eli Lilly’s Cyramza got its fifth FDA approval for in an advanced or metastatic cancer – this one for the second-line treatment of patients with hepatocellular carcinoma (HCC) who are AFP-High (AFP ≥400 ng/mL).
May 13, 2019
Medivir has positive data from basal cell carcinoma study
Swedish Medivir said Monday that positive data from the investigator-initiated study of remetinostat in basal cell carcinoma (BCC) patients has shown that remetinostat gel offers a potentially effective and well-tolerated, non-surgical intervention for treatment of localized BCCs.
May 10, 2019
BioSpecifics Technologies ends quarter with $4.4 million
BioSpecifics reported net income of $4.4 million for the first quarter 2019, compared to net income of $4.0 million, for the same period in 2018.
May 9, 2019
Recipharm launches Recipharm Inhalation SolutionsTM as its end-to-end offering for inhalation products
Recipharm, the contract development and manufacturing organisation (CDMO), has launched its end-to-end inhalation offering to provide customers with a fully integrated service from early stage development through to commercial manufacturing.
May 9, 2019
Dupixent licensed in the EU for severe asthma with type 2 inflammation
The European Commission (EC) has licensed Dupixent (dupilumab), developed by Regeneron and Sanofi, for older than 12 patients as an add-on maintenance treatment for severe asthma with type 2 inflammation.
May 9, 2019
Vibalogics increases capacity with a new 200L line for virus manufacturing
GERMANY-based contract development and manufacturing organization (CDMO) Vibalogics has increased its single-use bioreactor and purification capacity with a new manufacturing line to meet increasing demand for its specialist oncolytic virus and viral vector manufacturing services.
May 9, 2019
Denali reports net loss of $39M in Q1 2019
Denali has reported net loss of $39.0 million in the first quarter 2019, compared with a net loss of $23.7 million same period last year.